Filter posts

2009 - A Big Year for the BTK

The Amex Biotech Index, the BTK, outpaced its peer, the Nasdaq Biotech Index, by 29% …

Small Biotechs Spending Less

The median and mean operational cash spending for small public US biotechs (less than 250 …

1 in 4 Biotechs Above 100% - Waterfall Chart YTD

Year to date,  27% of biotech stocks have doubled in price. 65% are in positive …

The Rise and Fall of Undervaluation

If “price to cash” is a usable metric for fair value of a risky biotech …

The booming H1N1 vaccine market

The vaccine market is booming – and biotech companies are just one of the beneficiaries.  …

Perspectives on today's IPO candidates

Some speculation is coming back into the sector but most movement in public markets is …

Panelists make it personal

Panelists in the “Making it Personal” session discussed the clinical utility, comparative effectiveness implications and …

The race against pandemic flu

Panelists at this morning’s Therapeutic Workshop, “Predicting a Frontrunner in the Race Against Pandemic Flu” …

Positive results for Logical Therapeutics’ LT-NS001 vs. Naproxen clinical study

Logical Therapeutics, Inc. announced positive results of a Phase I/II clinical trial evaluating the gastrointestinal …

Endocyte awarded patent for vitamin receptor binding drug delivery conjugates

Endocyte, Inc. has been awarded a patent from the United States Patent and Trademark Office …